Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
Alecsat by CytoVac for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Alecsat is under clinical development by CytoVac and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...